The US Food and Drug Administration (FDA) has approved a new treatment combination for certain adults with metastatic prostate cancer, expanding treatment options for patients whose tumours carry specific genetic mutations.
The approval, announced on October 26, 2026, covers talazoparib, sold as Talzenna, in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or sensitive prostate cancer with homologous recombination repair (HRR) gene mutations.
Patients must have the relevant mutations confirmed using an FDA-authorised test before receiving the treatment.
Trial Shows Reduced Risk of Disease Progression
The FDA’s decision was based on findings from TALAPRO-3, a clinical trial involving 599 patients with HRR gene-mutated metastatic prostate cancer.
Participants received enzalutamide together with either talazoparib or a placebo, while all patients continued androgen deprivation therapy.
Results showed a significant improvement in radiographic progression-free survival among patients who received the talazoparib combination. The risk of disease progression or death was approximately 52% lower compared with patients who received enzalutamide and placebo.
At the time of the analysis, the median period without radiographic disease progression had not yet been reached among patients receiving the combination, compared with 45.8 months in the control group. Data on overall survival were not yet mature.
The treatment is specifically targeted at cancers with mutations in genes involved in repairing damaged DNA, including BRCA1 and BRCA2, among others.
The FDA noted that the prescribing information includes warnings about possible serious side effects, including bone marrow suppression and certain blood disorders.
The approval applies in the United States and does not automatically authorise the treatment for use in Nigeria, where medicines are subject to local regulatory requirements.
The development adds to growing efforts to use genetic information to guide treatment decisions for people living with advanced prostate cancer.
English